Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
2(33%)
Results Posted
100%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph early_phase_1
2
33%
Ph phase_1
2
33%
Ph phase_2
2
33%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
2(33.3%)
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)
Other(2)

Detailed Status

Terminated1
Active, not recruiting1
unknown1
Completed1
Suspended1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (33.3%)
Phase 12 (33.3%)
Phase 22 (33.3%)

Trials by Status

terminated117%
active_not_recruiting117%
unknown117%
completed117%
suspended117%
recruiting117%

Recent Activity

2 active trials
Showing 5 of 6
recruitingearly_phase_1

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

NCT07017816
active_not_recruitingphase_2

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

NCT02340117
suspendedphase_1

A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors

NCT02354547
unknownearly_phase_1

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

NCT03554707
terminatedphase_2

Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma

NCT02340156
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07017816Early Phase 1

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

Recruiting
NCT02340117Phase 2

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

Active Not Recruiting
NCT02354547Phase 1

A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors

Suspended
NCT03554707Early Phase 1

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

Unknown
NCT02340156Phase 2

Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma

Terminated
NCT00470613Phase 1

Safety Study of Infusion of SGT-53 to Treat Solid Tumors

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6